Approach to the Patient with Achondroplasia— New Considerations for Diagnosis, Management, and Treatment

Journal: The Journal of Clinical Endocrinology & Metabolism, 2025, 110, e2309–e2316

Authors: Nadia Merchant, Julie Hoover-Fong and Ricki S. Carroll

License and source: This article is licensed under the Creative Commons Attribution 4.0 International License (CC BY 4.0).
https://creativecommons.org/licenses/by/4.0/

Original publication available via PubMed

Summery: The following summary and key takeaways were prepared by the C4B team to support understanding of the scientific publication and are intended for informational purposes only. They do not replace the original article or professional medical advice.

Achondroplasia is the most common form of disproportionate short stature caused by a specific FGFR3 gene change, usually new at conception. Typical features include short, bowed limbs, large head, and normal cognition. Serious early risks are foramen magnum narrowing, hydrocephalus, and sleep apnea, so infants need timely neurological exams, sleep studies, and imaging. Vosoritide, a drug that can increase linear growth, is now approved from birth, prompting more families to seek treatment; however, not all children respond, and treatment does not replace required surveillance for complications. Care should be coordinated by a medical home (often pediatric endocrinology or genetics) with multidisciplinary input and individualized counseling about benefits, limits, and timing of therapy.

Key Take Aways:
This article will provide valuable insights into:

1. Achondroplasia is caused by a recurrent FGFR3 variant and is often de novo.
2. Early screening for life‑threatening issues (foramen magnum stenosis, hydrocephalus, apnea) is essential in infancy.
3. Vosoritide is FDA‑approved to increase growth starting at birth, but responses vary and it hasn’t been shown to reduce medical/orthopedic complications.
4. Families may decline or delay treatment; shared, individualized counseling and realistic expectations are crucial.
5. Multidisciplinary, coordinated care and adherence to surveillance guidelines remain necessary despite available growth‑modulating therapies.